IDEAYA Biosciences, Inc. Deferred Revenue Recognized
IDEAYA Biosciences, Inc. (IDYA) reported Deferred Revenue Recognized of $15.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-04
- IDEAYA Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $6.56M.
- IDEAYA Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-09-30 was $207.83M.
- IDEAYA Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-06-30 was $0.00.
- IDEAYA Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $0.00.
- IDEAYA Biosciences, Inc. contract with customer, liability, revenue recognized for fiscal 2025 was $218.71M.
- IDEAYA Biosciences, Inc. contract with customer, liability, revenue recognized for fiscal 2023 was $23.40M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.42M 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $6.56M 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $218.71M 10-K · filed 2026-02-17 | |||
| 2025-09-30 | $207.83M 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $23.40M 10-K · filed 2026-02-17 | |||
| 2023-09-30 | $8.00M 10-Q · filed 2024-11-04 | $19.50M 10-Q · filed 2024-11-04 | ||
| 2023-06-30 | $3.50M 10-Q · filed 2024-08-06 | $11.40M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $7.90M 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |